ArticleNeurology2026
Acute Attack Treatment Escalation and Subsequent Relapse Risk in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAcute treatment for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) includes high-dose IV methylprednisolone (IVMP), with escalation to IV immunoglobulin (IVIG) and/or plasma exchange (PLEX) based on severity or incomplete response. We evaluated whether escalation at first attack influences disease course.
methodsWe conducted a retrospective single-center study of pediatric-onset MOGAD evaluated between 2015 and 2024. Patients were classified to (1) steroid-only or (2) steroid-plus (IVMP followed by IVIG, PLEX, or both). Outcomes included early (≤1 year) and overall relapses. Time-to-event analyses used Kaplan-Meier and adjusted Cox regression.
resultsNinety-six of 114 patients were included (58% female; median age 6.3 years [interquartile range (IQR) 4.1-11.3]; median follow-up 3.2 years [IQR 1.4-6.1]). Sixty-eight (71%) received steroid-only therapy and 28 (29%) escalation therapy. Relapses were more frequent with steroid-only treatment at 1 year (28% vs 4%; relative risk [RR] 7.80; 95% CI 1.10-55.3) and at final follow-up (43% vs 11%; RR 3.98; 95% CI 1.33-11.93). Escalation therapy was associated with reduced relapse risk (adjusted hazard ratio [HR] 0.25; 95% CI 0.07-0.85; DISCUSSION: Acute immunotherapy escalation was associated with lower early and mid-term relapses, suggesting the first attack may represent a therapeutic opportunity to influence disease trajectory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.